Thursday July 19, 2018

To Counter AIDS Epidemic, Over Half of People With HIV Taking Drugs: UN

0
//
61
FILE - A mother gets an antiretroviral (ARV) drugs at the Chris Hani Baragwanath Hospital, South Africa's largest public hospital, in Soweto, May 16, 2012. VOA
Republish
Reprint
  • AIDS deaths are also now close to half of what they were in 2005, according to the U.N. AIDS agency
  • The Trump administration has proposed a 31 percent cut in contributions to the U.N. starting in October
  • About 19.5 million people with HIV were taking AIDS drugs in 2016, compared to 17.1 million the previous year

South Africa, July 20, 2017: For the first time in the global AIDS epidemic that has spanned four decades and killed 35 million people, more than half of all those infected with HIV are on drugs to treat the virus, the United Nations said in a report released Thursday.

AIDS deaths are also now close to half of what they were in 2005, according to the U.N. AIDS agency, although those figures are based on estimates and not actual counts from countries. Further to counter the AIDS epidemic, people are also looking for HIV home tests so that medications related to HIV can be started in the early stages.

Experts applauded the progress, but questioned if the billions spent in the past two decades should have brought more impressive results. The U.N. report was released in Paris where an AIDS meeting begins this weekend.

ALSO READ: Indian Origin Researcher part of team that developed a Test sensitive enough to detect “hidden” HIV

“When you think about the money that’s been spent on AIDS, it could have been better,” said Sophie Harman, a senior lecturer in global health politics at Queen Mary University in London.

She said more resources might have gone to strengthening health systems in poor countries.

“The real test will come in five to 10 years once the funding goes down,” Harman said, warning that countries might not be able to sustain the U.N.-funded AIDS programs on their own.

[bctt tweet=”AIDS deaths are also now close to half of what they were in 2005.” username=”NewsGramdotcom”]

The Trump administration has proposed a 31 percent cut in contributions to the U.N. starting in October.

According to the report, about 19.5 million people with HIV were taking AIDS drugs in 2016, compared to 17.1 million the previous year.

UNAIDS also said there were about 36.7 million people with HIV in 2016, up slightly from 36.1 million the year before.

In the report’s introduction, Michel Sidibe, UNAIDS’ executive director, said more and more countries are starting treatment as early as possible, in line with scientific findings that the approach keeps people healthy and helps prevent new infections. Studies show that people whose virus is under control are far less likely to pass it on to an uninfected sex partner.

“Our quest to end AIDS has only just begun,” he wrote.

The report notes that about three-quarters of pregnant women with HIV, the virus that causes AIDS, now have access to medicines to prevent them from passing it to their babies. It also said five hard-hit African countries now provide lifelong AIDS drugs to 95 percent of pregnant and breast-feeding women with the virus.

“For more than 35 years, the world has grappled with an AIDS epidemic that has claimed an estimated 35 million lives,” the report said. “Today, the United Nations General Assembly has a shared vision to consign AIDS to the history books.” The death toll from AIDS has dropped dramatically in recent years as the wide availability of affordable, life-saving drugs has made the illness a manageable disease.

But Harman said that “Ending AIDS” — the report’s title — was unrealistic.

“I can see why they do it, because it’s bold and no one would ever disagree with the idea of ending AIDS, but I think we should be pragmatic,” she said. “I don’t think we will ever eliminate AIDS so it’s possible this will give people the wrong idea.” (VOA)


NewsGram is a Chicago-based non-profit media organization. We depend upon support from our readers to maintain our objective reporting. Show your support by Donating to NewsGram. Donations to NewsGram are tax-exempt. 
Click here for reuse options!
Copyright 2017 NewsGram

Next Story

HIV Drug Is Not Linked to Depression: Study

A new study of a popular HIV drug could ease concerns about its link to depression

0
A doctor draws blood from a man to check for HIV/AIDS at a mobile testing unit in Ndeeba, a suburb in Uganda's capital, Kampala.
A doctor draws blood from a man to check for HIV/AIDS at a mobile testing unit in Ndeeba, a suburb in Uganda's capital, Kampala. VOA

A new study of a popular HIV drug could ease concerns about its link to depression. Researchers in Uganda found that efavirenz, once feared to lead to depression and suicide, did not cause the expected negative side effects in their patients.

Efavirenz is an affordable, once-a-day pill used around the globe to treat and prevent HIV/AIDS. It’s “the treatment of choice” in most of the world, according to Africa Health Research Institute’s Mark Siedner, “especially [in] countries that depend on global aid to treat HIV.”

But some fear that efavirenz may come with a cost.

Some studies in the United States and Europe found the drug increased patients’ risk of depression or suicide, although other studies did not.

The mixed results prompted many doctors in the United States to prescribe more expensive but potentially safer drugs.

Siedner wanted to take another look at the risk of depression, this time in an African population. From 2005 until 2015, he and a team of Ugandan and U.S. doctors tracked 694 patients who took either efavirenz or another antiretroviral medication. They regularly asked the patients whether they experienced depression or suicidal thoughts.

No difference

Their analysis, published in the Annals of Internal Medicine, showed there was no difference between the two treatments. Siedner told VOA, “In other words, efavirenz was not associated with a risk of depression. If anything, there seems to be a signal that potentially it was associated with a decreased risk. But it wasn’t a strong enough [signal] for us to say that.”

The authors also reported that of the 17 participants who died in the course of the study, not a single death was a suicide.

Siedner has two possible explanations for why their findings differed from those in Western countries. “One potential cause is that every single ethnic group in the world, of course, is different, and different in many different ways — different socially, different environmentally, and in this case they may be different genetically.” His team is looking at whether the genes that control metabolism of the drug have a role to play in this story.

HIV Aids is a deadly disease.
HIV virus is Not Linked To Depression. Flickr

A second explanation could be the effectiveness of the drug. Because efavirenz is so potent, it could be keeping people healthier than they expected, so patients are less likely to report negative emotions.

The study is important, said Anthony Fauci, who heads the National Institute of Allergy and Infectious Diseases, because it pushes back against “the initial observation of suicidal ideation and suicide and depression” as caused by efavirenz. He told VOA, “I think now what you’re seeing is that with these conflicting reports, it’s likely someone will come in [with] the proposal to do a randomized study and take a look. So the story isn’t ended with this paper.”

As more research on the safety of efavirenz is conducted, new and cheaper drugs that might replace it are on the horizon. One of them, dolutegravir, might also pose a risk, however. A study in Botswana found dolutegravir was linked to neural tube defects in embryos, meaning it might not be safe for pregnant women. As always, further research is needed to confirm whether this is a common problem or specific to the population studied in Botswana.

Also read: UNAIDS : World Is At A “Defining Moment” In A Battle Against HIV/AIDS

“I think the whole field right now is in a bit of a holding pattern,” Siedner said when asked about dolutegravir and the future of HIV medication. (VOA)